MTSL Issue 904

MTSL Issue 904 (dated 6/13/19) – This issue of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #FPRX #fiveprime #NKTR #nektar #ZIOP #ziopharm

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 16, 2019June 14, 2019 by conniebioinvest

MTSL Issue 902

MTSL Issue 902 (dated 5/16/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR FPRX #INCY #MYOV #NKTR #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 19, 2019May 17, 2019 by conniebioinvest

Pacira (PCRX) — HTX-011 CRL Continues To Widen EXPAREL’s Lead

Pacira (PCRX) – On Tuesday (4/30), Heron (HRTX) received a surprise Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for HTX-011 for the management of postoperative pain. The CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional CMC and non-clinical information.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 1, 2019June 28, 2019 by conniebioinvest

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there’s a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times. John McCamant discusses Sangamo in this article.

Posted on April 18, 2019July 16, 2019 by conniebioinvest

Sangamo (SGMO) — SGMO Firing On All Cylinders

BioInvest News – Sangamo (SGMO) has delivered excellent news across their proprietary ZFN drug development platform with promising human data from both the Hemophilia A program with Pfizer and Beta Thal with Sanofi.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on April 2, 2019May 8, 2019 by conniebioinvest

Novavax (NVAX) — ResVax Misses Primary Endpoint, Dropping Coverage

BioInvest News Novavax (NVAX) – This morning, NVAX reported disappointing top-line data from the ResVax Phase III PREPARE study for infant RSV prevention. Unfortunately, the trial failed on the primary endpoint of reducing medically significant RSV lower respiratory tract infection (LRTI).

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on February 28, 2019May 8, 2019 by conniebioinvest

Sangamo (SGMO) — Updated MPS I & II Trials Disappoint But ERT Withdrawals Continue & That’s Key

BioInvest News – Sangamo (SGMO) Updated MPS I & II Trials Disappoint But ERT Withdrawals Continue & Thatâ€™s Key, More Powerful 2nd Generation ZFNs in Clinic by Year-End, Stock Overreaction

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on February 7, 2019May 8, 2019 by conniebioinvest

Sangamo (SGMO) — JPM Update – WORLD, 5 Trials Underway, 4 More To Start

BioInvest News – Sangamo (SGMO) presented an overview of its clinical and technological gene therapy/editing leadership. With 5 trials underway and data from all five clinical results due this year, to us 2019 will be the year when SGMO gaps ahead of the gene editing crowd.

Posted on January 17, 2019January 29, 2019 by conniebioinvest

Madrigal (MDGL) Down Sharply After Positive Update at Liver Meeting

BioInvest BREAKING News (MDGL) – Down Sharply After Positive Update at Liver Meeting, Itâ€™s The Unforgiving Market, To Come More In Line With Sentiment & Current Price, Lowering BUY and Target

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 14, 2018September 20, 2019 by conniebioinvest

MTSL Issue 887

MTSL Issue 887 (dated 10/04/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #MDCO #XON #NKTR

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on October 7, 2018September 20, 2019 by conniebioinvest

Ionis (IONS) – IONS/AKCA Receive CRL From FDA for Waylivra Despite Positive AdCom

BioInvest BREAKING News – IONS/AKCA Receive CRL From FDA for Waylivra Despite Positive AdCom. In a somewhat surprising move, ONS/AKCA received a complete response letter (CRL) for Waylivra (volanesorsen) from the FDA. It is also unexpected given the 12-8 Advisory Committee vote in favor of approval on May 10th…

Posted on August 28, 2018January 29, 2019 by conniebioinvest

MTSL Issue 882

MTSL Issue 882 (dated 07/19/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #MDGL #MYOV #PCRX #SGMO #CRSP #EDIT #NTLA

Posted on July 22, 2018July 30, 2023 by conniebioinvest — 1 Comment

MTSL Issue 880

MTSL Issue 880 (dated 06/21/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #INCY #IONS #MDGL #NKTR #PCRX #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 24, 2018September 20, 2019 by conniebioinvest

NKTR- Nektar Down on ASCO ‘214 Combo Data Concerns Despite Advancing Into 3 Pivotal Trials

BioInvest BREAKING News – Nektar (NKTR) shares are down sharply as the ‘214/Opdivo combo data in the second cohort presented at ASCO is not as strong as the first cohort and the Company also failed to provide an update lung cancer.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 4, 2018March 3, 2019 by conniebioinvest

MTSL Issue 877

MTSL Issue 877 (dated 05/10/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #CELG #ESPR #FPRX #IONS #MDGL #MDCO #NKTR #PCRX #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 13, 2018September 20, 2019 by conniebioinvest

MTSL Issue 903

MTSL Issue 903 (dated 5/30/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #biomarin #BMRN #incyte #INCY #nektar #NKTR #sangamo #SGMO #ziopharm #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 2, 2019May 31, 2019 by conniebioinvest

The Medicines Company (MDCO) — ORION-3 3-Year Data Displays Compelling, Persistent LDL Reduction & Pristine Safety

The Medicines Company (MDCO) – MDCO presented interim results from Group 1 of the ORION-3 Phase II study (n=290) at the NLA (Miami) on Saturday. The long-term 3-year data showed that patients given additional inclisiran doses had LDL cholesterol reduced by >50% over time, consistent with the shorter-term ORION-1 results. (…more)

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 19, 2019October 18, 2019 by conniebioinvest

Alkermes (ALKS) — ALKS Misses on Aristada, Reports $30 Million After Guiding For $40 Million, Stock Selloff Overdone

This morning ALKS released their Q1:19 financial results that showed a big miss for Aristada coming in at $30 million after guiding for $40 million. While a disappointment, the company did not change overall FY guidance and stated that an inventory work down was the primary cause.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on April 25, 2019May 8, 2019 by conniebioinvest

Ionis (IONS) — IONS Down on Competitive Threat From NVS’ Zolgensma For Sprinraza

Ionis (IONS) — An update from Spinraza competitor Zolgensma (NVS) and the shift out of health care stocks are driving today’s decline. Shares are down 14% after Novartis presented a positive update to its STRIVE study for Spinal Muscular Atrophy (SMA) yesterday at the MDA 2019 meeting.

Posted on April 17, 2019May 8, 2019 by conniebioinvest

MTSL Issue 898

MTSL Issue 898 (dated 3/14/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #XON #IONS #PCRX #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on March 17, 2019March 15, 2019 by conniebioinvest

MTSL Issue 896

MTSL Issue 896 (dated 2/14/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #alkermes #INCY #incyte #MYOV #myovant #NKTR #nektar #PCRX #pacira #SGMO #sangamo #ZIOP #ziopharm

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on February 17, 2019February 15, 2019 by conniebioinvest

MTSL Issue 895

MTSL Issue 895 (dated 1/31/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #ionis #NVAX #novavax #SGMO #sangamo #MDCO #medicinescompany

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on February 3, 2019February 1, 2019 by conniebioinvest

MTSL Issue 891

MTSL Issue 891 (dated 11/29/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #BMRN #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on December 2, 2018September 20, 2019 by conniebioinvest

MTSL Issue 889

MTSL Issue 889 (dated 11/01/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #BMRN #ESPR #INCY #IONS

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 4, 2018September 20, 2019 by conniebioinvest

MTSL Issue 886

MTSL Issue 886 (dated 09/20/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #FPRX #MDGL #MDCO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on September 21, 2018September 20, 2019 by conniebioinvest

MTSL Issue 884

MTSL Issue 884 (dated 08/23/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #FPRX #IONS #NKTR #NVAX #MDGL #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on August 26, 2018September 20, 2019 by conniebioinvest

Sangamo (SGMO) – Sangamo (SGMO), CRSPR (CRSP), Editas (EDIT), Intellia (NTLA)

BioInvest BREAKING News â€“ FDA Releases Gene Therapy Guidelines & NATURE Publishes Damning CRSPR Research
BUY SGMO and SHORT CRSP, EDIT, NTLA.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on July 19, 2018January 29, 2019 by conniebioinvest

Sangamo (SGMO) – CRSPR Cancer Risk Only Further Distiguishes SGMO’s Competitive Edge In Gene Editing

BioInvest BREAKING News – Sangamo shares are weaker this morning due to what we believe should be causing the exact the opposite stock reaction after STAT News wrote a paper highlighting the potential side effects of CRSPR. The article(s) have nothing to do with SGMO’s ZFN gene editing technology. We suggest subscribers use the weakness in SGMO to…

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 13, 2018 by conniebioinvest

Madrigal (MDGL) 3196 Delivers Best-in-Class Phase II NASH Data

BioInvest BREAKING News â€“ This morning, Madrigal (MDGL) reported excellent top-line, 36-week results from a Phase II trial in patients with biopsy-proven non-alcoholic steatohepatitis (NASH). This is the best and most highly significant NASH data ever.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 31, 2018September 20, 2019 by conniebioinvest

Esperion – BA First Phase III Successful, But Stock Down on Safety Confusion & Some Efficacy Concerns

BioInvest BREAKING News – This morning, Esperion (ESPR) delivered positive Phase III safety data for bempedoic acid (BA). Despite delivering a highly significant 20% LDL reduction for those on treatment – expectations were for 20-30% LDL reduction based on several previous BA studies. The low-end for efficacy combined with safety concerns unrelated to treatment with the drug development candidate have driven the stock down by more than a third, and excessively in our view.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 2, 2018May 5, 2018 by conniebioinvest

BioMarin (BMRN) — Hem A Gene Therapy Update Is Good Enough

BioMarin (BMRN) – The widely anticipated BioMarin hemophilia A gene therapy delivered good news this morning, albeit with some caveats. BMRN announced both positive Phase I/II and Phase III data for ValRox (valoctocogene roxaparvovec) for adults with severe hemophilia A.

Posted on May 28, 2019June 28, 2019 by conniebioinvest

MTSL Issue 901

MTSL Issue 901 (dated 5/02/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #INCY #MDCO #PCRX

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 5, 2019May 3, 2019 by conniebioinvest

MTSL Issue 900

MTSL Issue 900 (dated 4/18/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #IONS #MDGL #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on April 19, 2019April 21, 2019 by conniebioinvest

MTSL Issue 899

MTSL Issue 899 (dated 4/04/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #XON #NKTR #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on April 7, 2019April 19, 2019 by conniebioinvest

MTSL Issue 897

MTSL Issue 897 (dated 2/28/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: ACAD, ALKS, FRPX, IONS, MDGL, NKTR, NVAX, PCRX, SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on March 3, 2019March 3, 2019 by conniebioinvest

Nektar (NKTR) — BMS/NKTR Release ‘214/Opdivo Urothelial Cancer Data in Front of ASCO GU

BioInvest News – NKTR’s stock is under pressure after the early update to NKTR’s Phase 2 PIVOT-02 trial of NKTR-214 in combination with Opdivo which includes 13 additional urothelial cancer (UC) patients vs. the 10 reported at ASCO 2018. The data remains solid despite the small decrease in ORR which is now 48% vs. 60% prior.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on February 12, 2019May 8, 2019 by conniebioinvest

MTSL Issue 894

MTSL Issue 894 (dated 1/17/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MYOV #NKTR #PCRX #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on January 19, 2019January 31, 2019 by conniebioinvest

MTSL Issue 890

MTSL Issue 890 (dated 11/15/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #IONS #MDGL #NKTR #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on November 18, 2018September 20, 2019 by conniebioinvest

MTSL Issue 888

MTSL Issue 888 (dated 10/18/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #FPRX #IONS #MYOV #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on October 21, 2018September 20, 2019 by conniebioinvest

MTSL Issue 885

MTSL Issue 885 (dated 09/06/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ESPR #IONS #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on September 9, 2018September 20, 2019 by conniebioinvest

MTSL Issue 883

MTSL Issue 883 (dated 08/02/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #IONS #MDCO #NKTR #PCRX #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on August 5, 2018September 20, 2019 by conniebioinvest

MTSL Issue 881

MTSL Issue 881 (dated 07/05/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ALKS #IONS #MDCO #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on July 8, 2018September 20, 2019 by conniebioinvest

MTSL Issue 879

MTSL Issue 879 (dated 06/07/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #FPRX #IONS #INCY #MDGL #NKTR #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on June 10, 2018September 20, 2019 by conniebioinvest

MTSL Issue 878

MTSL Issue 878 (dated 05/24/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #BMRN #ESPR #XON #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on May 27, 2018September 20, 2019 by conniebioinvest